Unicycive Stock Based Compensation from 2010 to 2024
| UNCY Stock | USD 0.68 0.09 15.25% |
Stock Based Compensation | First Reported 2010-12-31 | Previous Quarter 1.8 M | Current Value 887.9 K | Quarterly Volatility 550.2 K |
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
Unicycive | Stock Based Compensation |
Latest Unicycive Therapeutics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Unicycive Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Unicycive Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Unicycive Stock Based Compensation Regression Statistics
| Arithmetic Mean | 342,661 | |
| Geometric Mean | 77,841 | |
| Coefficient Of Variation | 160.57 | |
| Mean Deviation | 439,637 | |
| Median | 24,000 | |
| Standard Deviation | 550,220 | |
| Sample Variance | 302.7B | |
| Range | 1.7M | |
| R-Value | 0.76 | |
| Mean Square Error | 140.1B | |
| R-Squared | 0.57 | |
| Significance | 0 | |
| Slope | 92,902 | |
| Total Sum of Squares | 4.2T |
Unicycive Stock Based Compensation History
Other Fundumenentals of Unicycive Therapeutics
Unicycive Therapeutics Stock Based Compensation component correlations
Click cells to compare fundamentals
About Unicycive Therapeutics Financial Statements
Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 1.8 M | 887.9 K | |
| Stock Based Compensation To Revenue | 2.62 | 1.49 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.